Skip to main content
. 2006 Nov;119(3):404–411. doi: 10.1111/j.1365-2567.2006.02449.x

Figure 2.

Figure 2

HVEM-mediated activation is synergistic with TLR agonists or GM-CSF. (a) PMN (2 ×× 105/well) were added to titrated anti-HVEM in the presence of LPS (0·5 μg/ml) and the respiratory burst activity was analysed as before. (b) Analysis of the respiratory burst of PMN (2 × 105/well) in the presence of LPS (0·5 μg/ml) and anti-HVEM (10 μg/ml) either coated (filled circles), added in soluble form (sHVEM, 10 μg/ml) or in absence of anti-HVEM. (c) Respiratory burst of PMN (2 × 105/well) on anti-HVEM- (10 μg/ml) or control IgG- (10 μg/ml) coated plates in the presence of titrated amounts of LPS. (d–f) The respiratory burst of PMN (2 × 105/well) stimulated on anti-HVEM- or control IgG-coated plates in the presence of: (d) TLR2 agonist Pam3Cys (500 ng/ml), (e) TLR7 agonist imiquimod (10 μg/ml) or (f) GM-CSF (100 U/ml). All data are depicted as mean + SD from triplicates and are representative of three independent experiments with different donors.